TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04257188

Intervention type: PROCEDURE
Intervention: minimally invasive vitrectomy under subtenon anaesthesia
Description: The safety and feasibility in terms of tolerance and pain sensation during the surgery as well as the possible perception of light and colour sensations in minimally invasive vitrectomy under sub-tenon anesthesia shall be investigated.

Intervention type: PROCEDURE
Intervention: minimally invasive vitrectomy under subtenon anaesthesia
Description: The safety and feasibility in terms of tolerance and pain sensation during the surgery as well as the possible perception of light and colour sensations in minimally invasive vitrectomy under sub-tenon anesthesia shall be investigated.
Study: NCT04232332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor injection,experimental
Description: Intramuscular injection once on the first day according to dose requirements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor injection,experimental
Description: Intramuscular injection once on the first day according to dose requirements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human nerve growth factor injection,single dose
Description: Intramuscular injection once on the first day according to dose requirements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human nerve growth factor injection,single dose
Description: Intramuscular injection once on the first day according to dose requirements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human nerve growth factor injection,single dose
Description: Intramuscular injection once on the first day according to dose requirements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human nerve growth factor injection,single dose
Description: Intramuscular injection once on the first day according to dose requirements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human nerve growth factor injection,single dose
Description: Intramuscular injection once on the first day according to dose requirements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human nerve growth factor injection,single dose
Description: Intramuscular injection once on the first day according to dose requirements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human nerve growth factor injection,multiple dose
Description: Intramuscular injection once daily for 7 days according to dose requirements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human nerve growth factor injection,multiple dose
Description: Intramuscular injection once daily for 7 days according to dose requirements
Study: NCT04459208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manta
Description: plug-based vascular closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProGlide
Description: suture-based vascular closure
Study: NCT02368561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)
Description: US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
Study: NCT03595228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BN-Brachyury plus radiation
Description: MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.
Study: NCT00200356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Ozagrel
Description: Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
Study: NCT03495856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training For Chronic Pain
Description: 4-week group Mindfulness training program for adults with chronic pain
Study: NCT03550521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will be instructed to focus on the sensations of breathing. Subsequently, whenever their minds wander to distressing thoughts or emotions, they will be instructed to acknowledge those thoughts or emotions, and then bring their attention back to the sensations of breathing.
Study: NCT02321670

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: End-to-end
Description: Excision of the stricture and end-to-end anastomosis of the urethra.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Graft
Description: Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
Study: NCT02372227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-5584 and VS-6063
Description: Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT03316495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAMPHLET
Description: EXPOSURE TO PAMPHLETS
Study: NCT03808259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-ketamine Oral Thin Film
Description: (S)-ketamine OTF sublingual formulation at a dose of 7 mg, 14 mg, and 28 mg will be administered in sequential cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-ketamine IV Infusion
Description: (S)-ketamine IV solution will be infused at a dose of less than or equal to 14mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-ketamine IV Infusion
Description: (S)-ketamine IV solution will be infused at a dose of less than or equal to 14mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo.
Study: NCT03194737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift System Procedure
Description: Minimally invasive procedure in patients with acute urinary retention secondary to BPH.
Study: NCT02262208

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic Exercises
Description: Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.~Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test.

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic Exercises
Description: Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.~Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test.

Intervention type: OTHER
Group type: OTHER
Intervention: Eccentric Exercise
Description: Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.

Intervention type: OTHER
Group type: OTHER
Intervention: Eccentric Exercise
Description: Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)
Description: Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)
Description: Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.
Study: NCT02741973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: School sport
Study: NCT04341428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 20 mg
Description: DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 20 mg placebo
Description: DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 15 mg
Description: Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg Placebo
Description: Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks
Study: NCT00488553

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questions about cancer risk factors, medical history, and family history of cancer.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questions about cancer risk factors, medical history, and family history of cancer.
Study: NCT04286906

Intervention type: OTHER
Intervention: Questionnaire
Description: MultiDimensional Profile (MDP), Anxiety-Depression Hospital Scale (HADs), Nijmegen
Study: NCT04450381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rad-67 Pulse oximeter & DCI Mini sensor
Description: Noninvasive pulse oximeter that measures hemoglobin
Study: NCT02668211

Intervention type: DEVICE
Group type: OTHER
Intervention: PROFEMUR Preserve Classic Femoral Components
Study: NCT01962961

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PharmaNAC (N-acetylcysteine)
Description: PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.~PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PharmaNAC (N-acetylcysteine)
Description: PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.~PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Inactive pill that matches PharmaNAC on taste, color, and appearance.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Inactive pill that matches PharmaNAC on taste, color, and appearance.
Study: NCT00763698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickFlex Micro Model 1258T Left Heart Lead
Description: Implantation of QuickFlex Micro 1258T left heart lead in combination with a CRT-D system.
Study: NCT02190565

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food supplement
Description: Randomized double-blind, placebo-controlled

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Food supplement
Description: Randomized double-blind, placebo-controlled
Study: NCT03695770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kit for self-diagnosis and self-treatment
Description: distribution of kits for malaria self-diagnosis and self-treatment after a training by health facilitators
Study: NCT03367468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Strengthening exercises ( extrinsic and intrinsic foot muscles) Stretcthing exercises (plantar fascia, plantar flexor muscles)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Antero-posterior gliding, talocrural traction, metatarsal mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Antero-posterior gliding, talocrural traction, metatarsal mobilization
Study: NCT03859947

Intervention type: DEVICE
Intervention: Heated humidiﬁed high-flow nasal cannula
Description: Non-invasive ventilation with a nasal cannula
Study: NCT01515644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powder based infant formula
Description: Powder based infant formula with Inulin I

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powder based infant formula
Description: Powder based infant formula with Inulin II

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Powder based infant formula
Description: Powder based infant formula without Inulin
Study: NCT03666156

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention
Study: NCT00781573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel, 75 mg QD, for one year
Study: NCT03541395

Intervention type: DRUG
Group type: OTHER
Intervention: GnRH antagonist
Study: NCT01125488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Description: levonorgestrel-releasing intrauterine system (LNG-IUS) 52mg, duration 5 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist (triptorelin)
Description: GnRH agonist (triptorelin 3.75 mg, sc q28day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin)
Description: GnRH agonist (triptorelin 3.75 mg, sc q28day)
Study: NCT06521528

Intervention type: DEVICE
Intervention: nProfiler I Stomach Cancer Assay Kit
Description: nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
Study: NCT03597204

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fecal immunochemical test (FIT)
Description: Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
Study: NCT00776919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin / benzoyl peroxide gel
Description: Once a day application to the face

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin gel
Description: Once a day application to the face

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPO gel
Description: Once a day application to the face

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: Once a day application to the face
Study: NCT03705013

Intervention type: OTHER
Intervention: Cologuard
Description: Observational

Intervention type: OTHER
Intervention: Cologuard
Description: Observational

Intervention type: OTHER
Intervention: Cologuard
Description: Observational

Intervention type: OTHER
Intervention: Cologuard
Description: Observational
Study: NCT04291404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Distraction therapy using a Virtual Reality (VR) device
Study: NCT00665808

Intervention type: DRUG
Intervention: insulin detemir
Description: Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany

Intervention type: DRUG
Intervention: isophane human insulin
Description: Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany
Study: NCT02704143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination of Cyberknife with S-1
Description: Radiation therapy combined with chemotherapy
Study: NCT02509117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06751979 single ascending dose
Description: PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo single dose
Description: Matched Placebo solution/suspension administered as single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06751979 multiple ascending dose
Description: PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple dose
Description: Matched Placebo (solution/suspension)administered daily for 14 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple dose
Description: Matched Placebo (solution/suspension)administered daily for 14 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06751979 multiple dose
Description: PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06751979 multiple dose
Description: Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.
Study: NCT04354597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ & AZ
Description: Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.
Study: NCT03941704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulse-based diet
Description: Low Glycemic Index

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular diet
Description: Moderate Glycemic Index
Study: NCT03163017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2D Fluoroscopy
Description: Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al i.e. 2D Fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Fluoroscopy
Description: After the attending surgeon is satisfied with the reduction quality from 2D Fluoroscopy, 3D fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system will be used to generate additional images to assess syndesmotic and fibular reductions.
Study: NCT03535246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engineered Immune Cells
Description: Engineered immune effector cells (EIE)
Study: NCT02636361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro (Humalog)
Description: Administered SC
Study: NCT01396057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. It was suitable for single use only and the content of the vial was not allowed to be split

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone Implant
Description: Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection: Empty sterile syringes were provided so that masking could be maintained. Either empty syringes in the case of sham injections or pre-filled syringes in the case of ranibizumab injections were visible to the patient in the room of study drug administration
Study: NCT02045641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pleuracentesis
Description: Direct needle drainage of pleural effusions with dynamic ultrasound technique
Study: NCT00416039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo at 0.2 mg/kg and morphine 0.5 mg/kg
Study: NCT04110535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: IV administration over 1 minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: IV administration over 1 minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: IV administration over 1 minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: IV administration over 1 minute

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV administration over 1 minute